From Tumor Immunology to Immunotherapy in Gastric and Esophageal Cancer
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F19%3A73590394" target="_blank" >RIV/61989592:15110/19:73590394 - isvavai.cz</a>
Result on the web
<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6337592/" target="_blank" >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6337592/</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3390/ijms20010013" target="_blank" >10.3390/ijms20010013</a>
Alternative languages
Result language
angličtina
Original language name
From Tumor Immunology to Immunotherapy in Gastric and Esophageal Cancer
Original language description
Esophageal and gastric cancers represent tumors with poor prognosis. Unfortunately, radiotherapy, chemotherapy, and targeted therapy have made only limited progress in recent years in improving the generally disappointing outcome. Immunotherapy with checkpoint inhibitors is a novel treatment approach that quickly entered clinical practice in malignant melanoma and renal cell cancer, but the role in esophageal and gastric cancer is still poorly defined. The principal prognostic/predictive biomarkers for immunotherapy efficacy currently considered are PD-L1 expression along with defects in mismatch repair genes resulting in microsatellite instability (MSI-H) phenotype. The new molecular classification of gastric cancer also takes these factors into consideration. Available reports regarding PD-1, PD-L1, PD-L2 expression and MSI status in gastric and esophageal cancer are reviewed to summarize the clinical prognostic and predictive role together with potential clinical implications. The most important recently published clinical trials evaluating checkpoint inhibitor efficacy in these tumors are also summarized.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
ISSN
1422-0067
e-ISSN
—
Volume of the periodical
20
Issue of the periodical within the volume
13
Country of publishing house
CH - SWITZERLAND
Number of pages
15
Pages from-to
1-15
UT code for WoS article
000459747700013
EID of the result in the Scopus database
2-s2.0-85058923686